Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 11/20 | 0.73 |
| ▸ | TTR | P02766 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
| ▸ | CDC25C | P30307 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24268388 | 0.91 | AHR (0.79) | AHRTTRALDH1A1LMNAKMT2A | |
| SCHEMBL20208918 | 0.91 | AHR (0.72) | AHRTTRALDH1A1LMNACDC25A | |
| SCHEMBL20209148 | 0.91 | AHR (0.72) | AHRTTRALDH1A1LMNACDC25A | |
| SCHEMBL30170495 | 0.91 | AHR (0.72) | AHRTTRALDH1A1LMNACDC25A | |
| SCHEMBL22737968 | 0.91 | AHR (0.78) | AHRTTRALDH1A1LMNACDC25A | |
| SCHEMBL2282515 | 0.91 | AHR (0.78) | AHRTTRALDH1A1LMNAKMT2A | |
| SCHEMBL22078192 | 0.88 | AHR (0.69) | AHRTTRALDH1A1LMNACDC25A | |
| SCHEMBL21756020 | 0.86 | AHR (0.61) | AHRTTRCDC25ACDC25CMCL1 | |
| SCHEMBL21668972 | 0.86 | AHR (0.61) | AHRTTRCDC25ACDC25CMCL1 | |
| SCHEMBL23658447 | 0.86 | AHR (0.61) | AHRTTRALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5833994-A | TREATMENT OF HIV INFECTIONS, AIDS | PARACELSIAN, INC. (US) | 1998-11-10 | — | — | US | claimed |
| WO-1998030213-A2 | USE OF THE AH RECEPTOR AND AH RECEPTOR LIGANDS TO TREAT OR PREVENT THE CYTOPATHICITY OF VIRAL INFECTION | PARACELSIAN, INC. (US) | 1998-07-16 | — | — | WO | claimed |
| US-20240092728-A1 | HYDROXY-SUBSTITUTED SPHINGOLIPIDS | EVONIK OPERATIONS GMBH (DE) | 2024-03-21 | — | — | US | disclosed |
| EP-4274541-A1 | HYDROXY-SUBSTITUTED SPHINGOLIPIDS | Evonik Operations GmbH (DE) | 2023-11-15 | — | — | EP | disclosed |
| CN-116669690-A | Hydroxy-substituted sphingolipids | 赢创运营有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023130142-A2 | COMPOSITIONS AND METHODS USING CANNABINOID COMPOUNDS FOR TREATING URINARY TRACT DISORDERS | BRYANT CYNTHIA W (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230172065-A1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEM, LTD. (KR) | 2023-06-01 | — | — | US | disclosed |
| US-20230172065-A1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEM, LTD. (KR) | 2023-06-01 | — | — | US | disclosed |
| WO-2022148758-A1 | HYDROXY-SUBSTITUTED SPHINGOLIPIDS | EVONIK OPERATIONS GMBH (DE) | 2022-07-14 | — | — | WO | disclosed |
| US-6140063-A | USE OF THE ARYL HYDROCARBON (AH) RECEPTOR PROTEIN COMPLEX AS A DRUG TARGET, ALONE OR IN COMBINATION WITH ANOTHER COMPOUND, TO TREAT CYTOPATHIC CELL CHANGES AND VIRAL INFECTIONS GENERALLY | PARACELSIAN, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-5833994-A | TREATMENT OF HIV INFECTIONS, AIDS | PARACELSIAN, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| WO-1998030213-A2 | USE OF THE AH RECEPTOR AND AH RECEPTOR LIGANDS TO TREAT OR PREVENT THE CYTOPATHICITY OF VIRAL INFECTION | PARACELSIAN, INC. (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172065-A1 | ORGANIC LIGHT EMITTING DEVICE | CRY1, CYP1A2, CYP1A1 | AHR 474/4885TTR 3768/4885ALDH1A1 14/4885 |
| US-20240092728-A1 | HYDROXY-SUBSTITUTED SPHINGOLIPIDS | SPTLC1, ASAH2, ASAH1 | AHR 1549/4885TTR 4173/4885ALDH1A1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.